Loscocco et al., in their study, examined SNPs in genes from the ABC family (ABCB1, ABCG2, ABCC1, ABCC2) to determine their effectiveness in treatment with another tyrosine kinase inhibitor—nilotinib—in a group of 90 CML patients. Here, ABCC1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.